In a nutshell This study evaluated the risk of cardiovascular disease mortality among long-term survivors of classical Hodgkin lymphoma (cHL). The data showed that patients with early-stage HL are at a higher risk of mortality from cardiovascular disease than from cancer. Some background cHL is a cancer that starts in white blood cells called...
Read More
In a nutshell This study evaluated the effectiveness and safety of penpulimab (AK105) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that penpulimab was effective and safe with manageable side effects in these patients. Some background Classical Hodgkin lymphoma (cHL) is a cancer of...
Read More
In a nutshell This study assessed the accuracy of whole-body (WB) magnetic resonance imaging (MRI) in evaluating the treatment response of blood cancers. The data indicated that WB-MRI had a high diagnostic performance for assessing the treatment response of blood cancers and its addition was strongly linked to better diagnostic...
Read More
In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell The study aimed to investigate the rate of response (seroconversion) to SARS-Cov-2 vaccination in patients with blood cancers. This study concluded that seroconversion rates in these patients were significantly lower than that of healthy controls. Some background The severe acute respiratory syndrome...
Read More
In a nutshell This study evaluated the cognitive (mental abilities) function of long-term survivors of Hodgkin lymphoma (HL). The data showed that long-term survivors of HL with inactive employment status and older age showed impaired cognitive function. Some background HL is a cancer that involves the lymphatic system and affects how...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of brentuximab-vedotin (Bv; Adcetris) combined with bendamustine (Treanda: B) as salvage treatment in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and effective in these patients....
Read More
In a nutshell The study aimed to investigate if immunocompromised patients with blood cancers benefit from COVID-19 vaccination. This study concluded that these patients should not be excluded from COVID-19 vaccination. Some background Patients with blood cancers are at high risk for severe forms of COVID-19 disease due to lower...
Read More
Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update. Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...
Read More
In a nutshell This study investigated the risk of developing a range of thyroid disorders in both childhood and adult-treated female survivors of Hodgkin lymphoma (HL). The data showed that the risk of developing thyroid disorders increased significantly over time in both childhood and adult-treated survivors of HL. Some background Hodgkin lymphoma...
Read More
In a nutshell This study compared the health-related quality of life (HR-QoL) outcomes between pembrolizumab (Keytruda) and brentuximab vedotin (BV; Adcetris) in patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab improved the HR-QoL outcomes compared to BV in these patients. Some...
Read More
In a nutshell This study investigated the potential benefits of radiotherapy (RT) for the treatment of patients with advanced-stage Hodgkin lymphoma (HL) who have achieved a complete metabolic response (CMR) after ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-based chemotherapy. The data showed no significant difference in patient outcomes...
Read More
